Hybridan Research: Sareum Holdings plc
Progress is reported on Sareum’s most advanced assets which are the foundation of its near-term clinical strategy and development priorities. The...
225 Views
Sareum Holdings — Broader pipeline, bigger milestones
Sareum Holdings’ H125 results (to 31 December 2024) summarised a period of operational progress and an improved capital position, with successful...
242 Views
Hybridan Research: Sareum Holdings plc: Upping the Pace
There is a loss before tax reduced to £1.33m, compared to a loss of £2.5m (H123 to end Dec 2023) which included Phase 1a clinical trial costs.
221 Views
Sareum Holdings — New fund-raise and licence signal active 2025
Sareum Holdings has announced the acquisition of the licence for SRA737, a checkpoint kinase 1 (CHK1) inhibitor, in which the company had...
331 Views
Sareum Holdings PLC - Opportunistic Opportunity 13 March 2025
Sareum has now acquired this licence, and the economic terms have been renegotiated, so Sareum will receive a net 63.5% of all future revenues, up...
311 Views